Spark Therapeutics (ONCE) Earns “Overweight” Rating from Cantor Fitzgerald

Share on StockTwits

Cantor Fitzgerald reaffirmed their overweight rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note issued to investors on Thursday. The brokerage currently has a $80.00 price target on the biotechnology company’s stock, down from their prior price target of $103.00.

Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Spark Therapeutics from a hold rating to a sell rating in a research report on Wednesday, January 9th. Credit Suisse Group restated a hold rating and set a $44.00 price objective on shares of Spark Therapeutics in a research report on Monday, January 7th. William Blair restated a buy rating on shares of Spark Therapeutics in a research report on Monday, December 3rd. Raymond James restated a buy rating on shares of Spark Therapeutics in a research report on Monday, November 26th. Finally, Mizuho dropped their price objective on Spark Therapeutics to $62.00 and set a buy rating for the company in a research report on Wednesday, November 7th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock currently has an average rating of Buy and an average price target of $65.20.

ONCE opened at $43.36 on Thursday. The firm has a market cap of $1.67 billion, a PE ratio of -5.68 and a beta of 1.98. Spark Therapeutics has a 52-week low of $34.53 and a 52-week high of $96.59. The company has a current ratio of 10.71, a quick ratio of 10.36 and a debt-to-equity ratio of 0.09.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.04) by ($0.22). Spark Therapeutics had a negative return on equity of 14.18% and a negative net margin of 127.82%. The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $27.44 million. During the same period last year, the company posted ($1.90) earnings per share. The business’s revenue for the quarter was up 463.2% compared to the same quarter last year. Equities analysts forecast that Spark Therapeutics will post -1.53 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of the business. Teachers Advisors LLC raised its position in Spark Therapeutics by 1.4% in the third quarter. Teachers Advisors LLC now owns 66,153 shares of the biotechnology company’s stock valued at $3,609,000 after purchasing an additional 917 shares during the last quarter. Smith Asset Management Group LP raised its position in Spark Therapeutics by 39.6% in the third quarter. Smith Asset Management Group LP now owns 3,950 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 1,120 shares during the last quarter. Capital Fund Management S.A. raised its position in Spark Therapeutics by 8.1% in the second quarter. Capital Fund Management S.A. now owns 15,379 shares of the biotechnology company’s stock valued at $1,273,000 after purchasing an additional 1,152 shares during the last quarter. Metropolitan Life Insurance Co. NY raised its position in Spark Therapeutics by 13.1% in the second quarter. Metropolitan Life Insurance Co. NY now owns 10,207 shares of the biotechnology company’s stock valued at $845,000 after purchasing an additional 1,180 shares during the last quarter. Finally, California Public Employees Retirement System raised its position in Spark Therapeutics by 3.3% in the second quarter. California Public Employees Retirement System now owns 40,800 shares of the biotechnology company’s stock valued at $3,377,000 after purchasing an additional 1,300 shares during the last quarter.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Its products include LUXTURNA (voretigene neparvovec), which is in Phase III clinical trial for the treatment of genetic blinding conditions caused by mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia.

Further Reading: What is the Federal Reserve?

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply